PDCD1 and urinary bladder cancer: Programmed cell death-1(PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors have shown a lasting anti-tumor response and can improve the survival rate in several malignant tumors including kidney cancer, bladder cancer, melanoma, and lung cancer (8).